Evidence is Knowledge, Knowledge is Evidence

Migraine

Migraine is the most common form of headache largely affecting urban population. About 15-17% of women and 5-7% of men are affected by this disorder. Though migraine may occur in all age groups, it is highly prevalent in the age group of18-45 years. Migraine attacks are characterized by recurrent headaches, unilateral/bilateral location, pulsating in nature with moderate to severe intensity causing debility. World Health Organization has ranked migraine as 19th among the debility causing diseases.

There is no known cause for migraine. Though, diverse theories are brought forward time to time by experts. Yet none of these are able to provide long-term prophylactic treatment. On the contrary, the prolonged use of painkillers further triggers the Medication Overuse Headache (MOH) or other side effects.

In mid 80's a co-relation was made between Sleshma pitta & Migraine and an Ayurvedic Treatment Protocol (ATP) was developed. It comprises of Aahar (diet), Vihaar (lifestyle), Aushadh (Ayurvedic formulations - AFs). The path-making results of ATP for migraineurs are scientifically acknowledged. The results were presented in poster forms at 52nd Annual Scientific Meeting of the American Headache Society, Los Angeles, USA June 2010, 13th International Congress on Headache Stockholm, Sweden, June / July 2007 and at 16th International Symposium on Migraine, London, UK September 2006. The poster abstracts got published in medical journal Cephalalgia, 2006 volume 26, number 11, P 1367, Cephalalgia, 2007 volume 27, number 6, P 745 and Headache 2010 volume 50 (Supplement 1), P 53. Two peer reviewed research articles have also been published entitled as Response to Ayurvedic therapy in the treatment of migraine without aura, in International Journal of Ayurveda Research 2010, volume 1 issue 1, P 30-36 and Case studies on prophylactic ayurvedic therapy in migraine patients in International Journal of Genuine Traditional Medicines, 2012 volume 2, issue 2-e17, p 1-5.

AFs used in the treatment of migraine have undergone acute (96 hrs), sub acute (28 days) and sub chronic (210 days) toxicology studies following OECD guidelines at Bombay College of Pharmacy. The study shows that AFs are absolutely safe up to ten times to the given doses in human beings. The finding has been accepted for publication in a scientific journal International Journal of Toxicology & Pharmaceutical Research, 2010 volume 2, Issue 2, June - August 2010.

ATP for migraine is available at Padaav – Speciality Ayurveda Treatment Centres across the country through proficiently trained Ayurvedic physicians. Efforts are being made with leading institute(s) to develop this innovation for mass uses following WHO guidelines. Collaborative experimental and clinical studies are in progress in association with Department of Pharmacology and Department of and Neurology at All India Institute of Medical Sciences, New Delhi.